

Wednesday, September 4, 2024
 Institut Pasteur
 205 Rue de Vaugirard, 75015 Paris, France

AGENDA

11:15 AM	Registration and Lunch	
12:30 PM	Introductory Remarks and Program Overview	
12:35 PM	Welcome, Introduction, Forum Updates, Program Overview, and Acknowledgments	<i>Sehyr Khan & Veronica Miller, Forum</i>
12:40 PM	Opening Remarks	<i>Michelle Long, Novo Nordisk; Veronica Miller, Forum; Arun Sanyal, Virginia Commonwealth University</i>
12:40 PM	Session I: Meaningful Patient Engagement in Drug Development: Leading Through Example (PEDDLE)	
12:40 PM	Moderators: Michael Betel, Fatty Liver Alliance; Henry Chang, Fatty Liver Foundation*; Rosemarie Sellati, Regeneron	
12:40 PM	Working Group Introduction	<i>Michael Betel, Fatty Liver Alliance & Henry Chang, Fatty Liver Foundation*</i>
12:45 PM	Case Study #1	<i>Becky Taub, Madrigal Pharmaceuticals</i>
12:55 PM	MASH POWER Council Regeneron "Insights to Impact" Case Study	<i>Rosemarie Sellati, Regeneron</i>
1:05 PM	Panel Discussion	<i>Luiza Borowksa, Boehringer Ingelheim; Michael Cooreman, Inventiva Pharma; Helene Jordan, American Liver Foundation; Michelle Long, Novo Nordisk; Gina Madison, NASH KNOWledge; Jeff McIntyre, Global Liver Institute; Milan Mishkovidj, ELPA; Becky Taub, Madrigal Pharmaceuticals; Jose Willemse, Liver Patients International</i>
1:35 PM	Q&A	<i>All attendees</i>
1:45 PM	Wrap Up & Next Steps	<i>Michael Betel, Fatty Liver Alliance; Henry Chang, Fatty Liver Foundation*; Rosemarie Sellati, Regeneron</i>
1:50 PM	Session II: Towards Consensus on NITs	
1:50 PM	Moderators: Veronica Miller, Forum & Arun Sanyal, Virginia Commonwealth University	
1:50 PM	Proposal of NITs for a Reasonably Likely Surrogate Endpoint	<i>Richard Haubrich, Forum & Michelle Long, Novo Nordisk</i>
2:05 PM	LSM by VCTE as a Reasonably Likely Surrogate Endpoint: Review of the latest clinical evidence	<i>Céline Fournier, Echosens</i>
2:15 PM	MRE: Current Data	<i>Michael Middleton & Claude Sirlin, UCSD</i>
2:25 PM	Mapping VCTE and FIB-4 thresholds to matching ELF™ cutoffs	<i>Matthew Gee, Siemens Healthineers</i>
2:35 PM	Break	
3:05 PM	Panel Discussion	<i>Quentin Anstee, Newcastle University; Laurent Castera, University of Paris-VII; Michael Betel, Fatty Liver Alliance; Judith Ertle, Boehringer Ingelheim; Céline Fournier, Echosens; Matthew Gee, Siemens Healthineers; Michael Middleton, UCSD; Vlad Ratzu, Sorbonne Université; Claude Sirlin, UCSD; Jan Taminiau, EMA</i>
3:50 PM	Session III: Forum Placebo Arm Database Data Analysis Plans	
3:50 PM	Moderators: Michael Cooreman, Inventiva Pharma & Veronica Miller, Forum	

3:50 PM	Forum Placebo Arm Database Updates	<i>Richard Haubrich, Chris Hoffman, Veronica Miller, and Margot Yann, on behalf of the Data and Analysis Team</i>
4:40 PM	Open Discussion	<i>All attendees</i>
4:50 PM	Session IV: MetALD/ALD & Pediatric MASH Working Groups	
4:50 PM	Moderators: Judith Ertle, Boehringer Ingelheim & Michelle Long, Novo Nordisk	
4:50 PM	MetALD/ALD Working Group	<i>Maja Thiele, Odense University & Nikhil Vergis, GSK</i>
5:00 PM	MetALD/ALD Working Group Discussion	<i>Jenn Jones, Sober Livers*; Maja Thiele, Odense University & Nikhil Vergis, GSK</i>
5:30 PM	Pediatric MASH WG	<i>Stavra Xanthakos, Cincinnati Children's Hospital & Miriam Vos, Emory University</i>
5:45 PM	Pediatric MASH WG Discussion	<i>All attendees</i>
6:15 PM	What's Next?	
6:15 PM	Wrap Up	<i>Michelle Long, Novo Nordisk; Veronica Miller, Forum, Arun Sanyal, Virginia Commonwealth University</i>
6:25 PM	Networking Reception	
	*remote participation	